Viridian Therapeutics, Inc.
VRDN· Nasdaq
VRDNViridian Therapeutics, Inc.
Filed Mar 26, 2021 · 10-K · 85 days after period end · 0001590750-21-000029
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $54.00K | $880.00K | $476.00K | $1.19M |
| Net Income | -$90.74M | -$10.12M | -$10.32M | -$6.39M |
| EPS Diluted | — | -$0.31 | -$0.33 | -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 26, 2021 · 85 d after period end
